COMMUNIQUÉS West-GlobeNewswire

RYBREVANT®▼ par voie sous-cutanée (amivantamab) offre un taux de réponse global prometteur de 45 pour cent associé à une durée de réponse médiane de 7,2 mois dans le cancer de la tête et du cou récurrent ou métastatique
21/10/2025
Les réponses étaient rapides et durables, et une réduction tumorale a été observée chez 82 pour cent des patients 1 Les nouveaux résultats issus de cette étude expérimentale s’appuient sur la solidité des données [...]
RadNet to Host Investor Day on November 11, 2025
21/10/2025
LOS ANGELES, Oct. 21, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of outpatient imaging centers and [...]
PrestoDoctor Expands Into Michigan Ahead of New Cannabis Tax Changes
21/10/2025
Strategic market entry positions company for growth as Michigan prepares for 2026 tax reforms Mesquite, NV, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Mesquite, NV — October 21, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP) [...]
Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO
21/10/2025
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapies HTL0039732, was found to be well-tolerated, [...]
Acies Bio doubling biomanufacturing capacity with the construction of 30 m³ bioreactor
21/10/2025
KAMNIK, Slovenia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Acies Bio has begun the project for construction of facility with expanded fermentation and DSP capabilities with the largest 30 m³ bioreactor yet, marking a [...]
Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
21/10/2025
Saint-Genis-Pouilly, France, 21 October 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces that its Chief Scientific Officer, Philip Beer, will be [...]
Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers
21/10/2025
CPV-104 is the only recombinant Factor H in clinical development and has received EU Orphan Drug Designation for C3G Eleva successfully completed the Single Ascending Dose part of the First-in-Human clinical trial [...]
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
21/10/2025
– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety [...]
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
21/10/2025
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety [...]
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
21/10/2025
Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment 1 Data will be shared with regulatory [...]

Pages